In 2019, 50 percent of all new novel FDA drug approvals – 24 out of 48 new molecular entities – came from companies with a footprint in New Jersey.
BioNJ will honor each of these companies with an Innovator Award during its 27th Annual Dinner Meeting & Innovation Celebration on Feb. 6 at the Hilton East Brunswick.
BioNJ’s Annual Dinner Meeting will bring together 700 biotechnology and pharmaceutical professionals, academic leaders, service providers and government officials to celebrate groundbreaking medical innovation coming from the Garden State.
“We are so proud of New Jersey’s robust life sciences ecosystem which is responsible for exactly half of all of the 2019 novel innovations now making their way to patients with cancer, Parkinson’s disease, heart disease, multiple sclerosis and more, reinforcing the fact that the Garden State is the drug development capital of the world,” said BioNJ Chief Executive Officer and President Debbie Hart. “Our members are helping patients live longer, better lives while lessening the burden of illness and disease on society. We are pleased to celebrate their important work and dedication in this way.”
Innovator companies to be included include:
- Allergan for Ubrelvy
- Amgen for Evenity
- Bayer Healthcare for Nubeqa
- Beigene USA for Brukinsa
- Bristol-Myers Squibb for Inrebic and Reblozyl
- Daiichi Sankyo Inc. for Enhertu and Turalio
- Eisai Inc. for Dayvigo
- Eli Lilly for Reyvow
- Galderma Research and Development LLC for Aklief
- Janssen Biotech for Balversa
- Jazz Pharma for Sunosi
- Kyowa Kirin for Nourianz
- Merck & Co. for Recarbrio
- Novartis for Adakveo, Beovu, Piqray, Mayzent and Egaten
- Pfizer for Vyndaqel
- Sanofi for Cablivi
- Shionogi & Co. for Fetroja
- SK Life Science for Xcopri
